In our article, we reported that high urinary concentrations of 11-dehydrothromboxane B 2 were associated with an increased risk of cardiovascular events among high-risk patients treated with aspirin. 1 We agree with Dr Cattaneo that urinary 11-dehydrothromboxane B 2 is not a specific measure of platelet thromboxane production, and in our article we discuss how nucleated cells such as monocytes and vascular endothelial cells are also a potential source of thromboxane. 1 Cyclooxygenase-2 found in endothelial cells and monocytes is upregulated in inflammatory states and is an important potential mechanism of elevated urinary concentrations of 11-dehydrothromboxane B 2 despite aspirin therapy.
We are analyzing our data to ascertain whether high urinary concentrations of 11-dehydrothromboxane B 2 were associated with an increased risk of cardiovascular events after adjusting for known markers of inflammation, such as C-reactive protein. We are also exploring whether a high C-reactive protein was independently associated with high urinary concentrations of 11-dehydrothromboxane B 2 .
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